<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843632</url>
  </required_header>
  <id_info>
    <org_study_id>V210-058</org_study_id>
    <secondary_id>Merck Protocol Number</secondary_id>
    <nct_id>NCT03843632</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety, Tolerability and Immunogenicity of VARIVAX™ in Healthy Russians (V210-058)</brief_title>
  <official_title>An Open-label, Multicenter, Single-arm Study to Evaluate the Safety, Tolerability, and Immunogenicity of VARIVAX™ in Healthy Russian Individuals 12 Months of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, tolerablity, and immunogenicity of VARIVAX™ vaccine
      in healthy Russians aged 12 months and older.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">June 19, 2020</completion_date>
  <primary_completion_date type="Actual">June 19, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Varicella Zoster Virus (VZV) Antibody Response Rate</measure>
    <time_frame>6 weeks post-final vaccination (1-12 years old: 6 weeks; 13 years and older: 12 weeks)</time_frame>
    <description>Percentage of participants with VZV antibody ≥5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VZV Antibody Titer</measure>
    <time_frame>6 weeks post-final vaccination (1-12 years old: 6 weeks; 13 years and older: 12 weeks)</time_frame>
    <description>Geometric Mean Titer (GMT) of VZV Antibody</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VZV Antibody Seroconversion Rate</measure>
    <time_frame>6 weeks post-final vaccination (1-12 years old: 6 weeks; 13 years and older: 12 weeks)</time_frame>
    <description>Percentage of participants with VZV antibody ≥1.25 gpELISA units/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited injection-site reactions</measure>
    <time_frame>Up to 5 days after each vaccination.</time_frame>
    <description>Percentage of participants with injection-site redness, swelling, pain/tenderness of any intensity or size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited injection-site adverse experiences</measure>
    <time_frame>Up to 42 days after each vaccination.</time_frame>
    <description>Percentage of participants with injection-site adverse experiences, regardless of severity or causality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elevated Temperature</measure>
    <time_frame>Up to 28 days after each vaccination</time_frame>
    <description>Percentage of participants with maximum reported temperature ≥39.0°C oral equivalent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Varicella-like and herpes zoster-like rashes</measure>
    <time_frame>Up to 42 days after each vaccination.</time_frame>
    <description>Percentage of participants with varicella-like and herpes zoster-like rashes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse experiences</measure>
    <time_frame>Up to 42 days after each vaccination.</time_frame>
    <description>Percentage of participants with systemic adverse experiences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse experiences</measure>
    <time_frame>Up to 42 days after each vaccination.</time_frame>
    <description>Percentage of participants with serious adverse experiences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine-related serious adverse experiences</measure>
    <time_frame>Up to 42 days after each vaccination.</time_frame>
    <description>Percentage of participants with vaccine-related serious adverse experiences</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine-related death</measure>
    <time_frame>Up to 42 days after each vaccination.</time_frame>
    <description>Percentage of participants with vaccine-related death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>VARIVAX™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive one dose subcutaneous (sc) VARIVAX™ on Day 1. Participants 13 years and older will also receive a second dose sc VARIVAX™ on Day 43.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VARIVAX™</intervention_name>
    <description>All participants will receive one dose subcutaneous (sc) Varicella Virus Vaccine Live on Day 1. Participants 13 years and older will also receive a second dose sc Varicella Virus Vaccine Live on Day 43.</description>
    <arm_group_label>VARIVAX™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has a negative clinical history for varicella and herpes zoster

          -  females of reproductive potential have a negative pregnancy test prior to each study
             vaccination

          -  females of reproductive potential remain abstinent or use 2 acceptable methods of
             birth control during study until 3 months following last study vaccination

          -  females not of reproductive potential do not require a pregnancy test or use of
             contraceptives

          -  legal representative of adult or parent of children understands risks involved with,
             consent to participate in, and comply with the study procedures

        Exclusion Criteria:

          -  has a history of allergy or anaphylactic reaction to neomycin, gelatin, or any
             component of VARIVAX^TM

          -  has received any form of varicella or herpes zoster vaccine at any time prior to
             study, or anticipates receiving any during study

          -  has received immune globulin, a blood transfusion or blood derived products within
             prior 5 months or plans to do so during study

          -  has received aspirin or any aspirin-containing products within prior 14 days

          -  has been exposed to varicella or herpes zoster in the prior 4 weeks involving
             playmate, hospital or continuous household contact, or had contact with a newborn
             whose mother had chickenpox 5 days before or 2 days after delivery

          -  has, or lives with a person who has, any congenital or acquired immune deficiency,
             neoplastic disease, or depressed immunity including those resulting from
             corticosteroid use or other immunosuppressive therapy

          -  has received glucocorticosteroids for more than 5 consecutive days within prior 3
             months, or any dose of glucocorticoids within prior 7 days, or expects to use
             glucocorticosteroids during the study

          -  was vaccinated with licensed non-live or live vaccine within prior 30 days or expects
             vaccination during 42 day follow-up postvaccination period

          -  had a fever within 72 hours prior to study vaccination

          -  has participated in another trial within prior 30 days, is currently participating in
             another trial, or plans to participate in another trial during the planned study
             period for this trial

          -  is pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 5816)</name>
      <address>
        <city>Kazan</city>
        <zip>420140</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Children Infections ( Site 5801)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb Pasteur RI of Epidemiology and Microbiology ( Site 5817)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical University ( Site 5814)</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smolensk State Medical University ( Site 5815)</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

